CTRI/2023/01/048914尚未招募4 期
A Randomized, Double-Blind, Placebo-Controlled, Two-arm, Parallel Study to Evaluate Clinical Safety of Heat Inactivated Bacillus coagulans (Weizmannia coagulans) MTCC 5856 (Sami-Sabinsa Group Limited, India) in Healthy Human Participants.
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- The occurrence of adverse reactions
研究概览
简要总结
This is a Randomized, Double-Blind, Placebo-Controlled, Two-arm, Parallel Study to Evaluate the Clinical Safety of Heat Inactivated Bacillus coagulans (Weizmannia coagulans) MTCC 5856 in Healthy Human Participants. Healthy male/non-pregnant, non-lactating female aged between 18 to 49 years will be enrolled in the study. Participants shall be randomized in a ratio of 1:1 into one of the two treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 49.00 Year(s)（—）
- 性别
- All
入选标准
- •Healthy male or non-pregnant, non-lactating female participants aged between 18 to 49 years both inclusive and having Body Mass Index (BMI) ≤28 Kg/m
- •Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation at baseline measurement.
- •Participant willing to refrain from consuming probiotic and postbiotic supplements during the study.
- •Participant able to swallow and retain orally administered medication.
- •Female participant of childbearing potential practicing an approved method of contraception and willing to continue its use throughout the study duration or female participant of non-childbearing potential.
- •Participant willing and able to provide written informed consent before any study procedures are performed.
- •Participant shall be willing and able to understand and comply with the requirements of the study, consume the Investigational Product as instructed, return at the appropriate scheduled visits, comply with therapy prohibitions, and be able to complete the study.
排除标准
- •Females who are planning to become pregnant in three months or have a positive pregnancy test (females of childbearing potential) at screening.
- •Participant who has not taken two doses of vaccination for COVID-19 as per the government guidelines.
- •Participant education level below 8th grade of schooling.
- •Participant with or having a prior history of clinically significant diseases/disorders and/or any kind of allergy.
- •Participant with inflammatory, autoimmune diseases, diabetes, lactose intolerance, immune deficiency, hyperthyroidism or non-medically adjusted hypothyroidism, and coeliac disease.
- •Participant with or having a prior history of clinically significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological, or psychiatric disease.
- •History of organ transplantation.
- •Participant has undergone surgery during the last six months.
- •Use of antipsychotic medications within 3 months before the start of the study.
- •Use of systemic corticosteroids within 1 month before the start of the study.
- •11.Use of vitamin/ mineral/ dietary or herbal supplements within 15 days before the start of the study and not willing to refrain from the use of any new vitamins and/or minerals and/or dietary and/or herbal supplements during the study.
- •Allergy or Significant history of hypersensitivity or idiosyncratic reactions to any investigational product or its excipients etc.
- •History of difficulty in swallowing.
- •Smoking (≥ 10 cigarettes/day) or consumption of tobacco products (≥ 4 chews/day).
- •Alcohol dependence, alcohol abuse, or drug abuse or addiction to any recreational drug within the past 6 months.
- •Significantly abnormal 12 lead ECG findings.
- •Participant with clinically significant abnormal laboratory values.
- •Patients deemed uncooperative or noncompliant.
- •Participation in another clinical trial within the preceding 90 days of the study starts.
- •Any other condition that the Principal Investigator thinks may jeopardize the study.
结局指标
主要结局
The occurrence of adverse reactions
时间窗: Day 1 to Day 31 | Screening to Day 31
Change in vital signs, laboratory parameters
时间窗: Day 1 to Day 31 | Screening to Day 31
次要结局
- •Mean change in serum Immunoglobulin IgG levels between groups(•Mean change in serum Immunoglobulin IgE levels between groups)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
A Study to Assess the Effect of Libifem® (VL-GF-01) on Fertility in Women With Diminished Ovarian ReserveNCT06826716Vedic Lifesciences Pvt. Ltd.150
已完成
不适用
AÂ study to determine the efficacy and tolerability of LN19184 to improve cognition in adults.CTRI/2020/08/027368Laila Nutraceuticals100
Unknown
3 期
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19COVID-19NCT04353518Cadila Pharnmaceuticals4,000
已完成
不适用
A Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional ConstipationFunctional ConstipationNCT06730594Vedic Lifesciences Pvt. Ltd.168
已完成
不适用
A Study to Assess the Gut Health Effects of Oil Compound on Healthy AdultsGut HealthNCT05837754Vedic Lifesciences Pvt. Ltd.102